Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

Blood Cancer J. 2017 Dec 14;7(12):644. doi: 10.1038/s41408-017-0018-7.

¹ Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA. [email protected].
² Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
³ Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁵ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Division of Hematology and Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA.
⁷ Groupe Francophone des mylodysplasies and Service Hematologie Senior, Hopital Saint Louis, Paris, France.
⁸ Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT, USA.
⁹ Onconova Therapeutics, Inc., Newtown, PA, USA.
¹⁰ AOU Careggi, University of Florence, Florence, Italy.
¹¹ Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹² Universitätsklinikum Dresden, Dresden, Germany.

No abstract available

Publication types